Lefamulin. Comment on: “Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms. <i>Microorganisms</i>, 2019, <i>7</i>, 270”

Abstract

On 18 August 2019, an article was published in Microorganisms presenting novel, approved anti-Gram-positive antibiotics. On 19 August 2019, the U.S. Food and Drug Administration announced the approval of lefamulin, a representative of a new class of antibiotics, the pleuromutilins, for the treatment of adult community-acquired bacterial pneumonia. We present a brief description of lefamulin.

Keywords

• multidrug-resistance
• Gram-positive pathogens
• novel antibiotics
• pleuromutilins
• lefamulin